Anavex-2-73 free base, also known as Blarcamesine, is primarily investigated for its potential therapeutic applications in neurodegenerative diseases. It is being studied as a treatment for Alzheimer's disease due to its ability to modulate sigma-1 receptors, which play a role in cellular stress responses and neuroprotection. This modulation may help reduce cognitive decline and improve memory function in patients. Additionally, Blarcamesine is being explored for its potential in treating other neurological conditions, such as Parkinson's disease and Rett syndrome, due to its neuroprotective and anti-inflammatory properties. Its ability to enhance mitochondrial function and reduce oxidative stress further supports its application in addressing neurodegenerative disorders. Clinical trials are ongoing to evaluate its efficacy and safety in these contexts.